天士力(600535.SH):公司藥品擬中標國家藥品集中採購
格隆匯1月19日丨天士力(600535.SH)公告,按照國家醫保局、國家衞生健康委、國家藥監局、工業和信息化部、中央軍委後勤保障部《關於開展第二批國家組織藥品集中採購和使用工作的通知》(醫保發〔2020〕2號)要求,2020年1月17日,天士力醫藥集團股份有限公司(以下簡稱“公司”)參加了國家藥品集中採購投標工作。
公司全資子公司江蘇天士力帝益藥業有限公司(以下簡稱“江蘇天士力”)、控股子公司天津天士力(遼寧)製藥有限責任公司(以下簡稱“遼寧天士力”)已通過國家藥品監督管理局仿製藥質量和療效一致性評價的仿製藥品他達拉非與吲達帕胺擬中標本次集中採購。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.